EA201792312A1 - Конструкции на основе калихеамицина и способы их применения - Google Patents

Конструкции на основе калихеамицина и способы их применения

Info

Publication number
EA201792312A1
EA201792312A1 EA201792312A EA201792312A EA201792312A1 EA 201792312 A1 EA201792312 A1 EA 201792312A1 EA 201792312 A EA201792312 A EA 201792312A EA 201792312 A EA201792312 A EA 201792312A EA 201792312 A1 EA201792312 A1 EA 201792312A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
kaliheamicin
application
constructions based
constructions
Prior art date
Application number
EA201792312A
Other languages
English (en)
Inventor
Джулия Гаврилюк
Викрам Натварсинхджи Сисодия
Original Assignee
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭББВИ СТЕМСЕНТРКС ЭлЭлСи filed Critical ЭББВИ СТЕМСЕНТРКС ЭлЭлСи
Publication of EA201792312A1 publication Critical patent/EA201792312A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

В данном документе предусматриваются конъюгаты антитела и лекарственного средства (ADC), содержащие калихеамицин, и способы применения их же для лечения пролиферативных нарушений.
EA201792312A 2015-04-21 2016-04-21 Конструкции на основе калихеамицина и способы их применения EA201792312A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562150693P 2015-04-21 2015-04-21
PCT/US2016/028530 WO2016172273A1 (en) 2015-04-21 2016-04-21 Calicheamicin constructs and methods of use

Publications (1)

Publication Number Publication Date
EA201792312A1 true EA201792312A1 (ru) 2018-06-29

Family

ID=57144229

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792312A EA201792312A1 (ru) 2015-04-21 2016-04-21 Конструкции на основе калихеамицина и способы их применения

Country Status (20)

Country Link
US (1) US20180133337A1 (ru)
EP (1) EP3285807A4 (ru)
JP (1) JP2018515457A (ru)
KR (1) KR20170139110A (ru)
CN (1) CN107849146A (ru)
AR (1) AR104333A1 (ru)
AU (1) AU2016250537A1 (ru)
BR (1) BR112017022682A2 (ru)
CA (1) CA2983158A1 (ru)
CL (1) CL2017002680A1 (ru)
CO (1) CO2017010692A2 (ru)
EA (1) EA201792312A1 (ru)
HK (1) HK1246194A1 (ru)
IL (1) IL255161A0 (ru)
MA (1) MA41959A (ru)
PE (1) PE20180599A1 (ru)
PH (1) PH12017501930A1 (ru)
SG (1) SG11201708629VA (ru)
TW (1) TW201713363A (ru)
WO (1) WO2016172273A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200093934A1 (en) * 2017-05-10 2020-03-26 Sanofi Novel peptidic linkers and cryptophycin conjugates, their preparation and their therapeutic use
CN111683686A (zh) 2017-12-06 2020-09-18 西纳福克斯股份有限公司 烯二炔缀合物
NZ768778A (en) * 2018-05-30 2022-07-01 Abbvie Stemcentrx Llc Anti-sez6 antibody drug conjugates and methods of use
WO2020171757A1 (en) * 2019-02-18 2020-08-27 Medivir Aktiebolag Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6576746B2 (en) * 1998-10-13 2003-06-10 Immunomedics, Inc. Site-specific labeling of disulfide-containing targeting vectors
SI1507556T1 (sl) * 2002-05-02 2016-10-28 Wyeth Holdings Llc Konjugati kaliheamicinski derivat-nosilec
US8815226B2 (en) * 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9814784B2 (en) * 2013-01-03 2017-11-14 Celltrion, Inc. Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same
AU2014312215B2 (en) * 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions

Also Published As

Publication number Publication date
MA41959A (fr) 2018-02-28
JP2018515457A (ja) 2018-06-14
AR104333A1 (es) 2017-07-12
SG11201708629VA (en) 2017-11-29
EP3285807A4 (en) 2018-12-26
CA2983158A1 (en) 2016-10-27
PE20180599A1 (es) 2018-04-09
HK1246194A1 (zh) 2018-09-07
CN107849146A (zh) 2018-03-27
CL2017002680A1 (es) 2018-04-27
AU2016250537A1 (en) 2018-11-08
KR20170139110A (ko) 2017-12-18
PH12017501930A1 (en) 2018-03-19
BR112017022682A2 (pt) 2018-07-10
IL255161A0 (en) 2017-12-31
EP3285807A1 (en) 2018-02-28
WO2016172273A1 (en) 2016-10-27
TW201713363A (zh) 2017-04-16
CO2017010692A2 (es) 2018-01-31
US20180133337A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
CY1121907T1 (el) Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων
DOP2021000023A (es) Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
PH12018500815A1 (en) Antibody conjugates comprising toll-like receptor agonist
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
UY37278A (es) Anticuerpos anti-b7-h3 y conjugados de fármaco y anticuerpos
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
PH12016500781A1 (en) Novel anti-claudin antibodies and methods of use
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
PH12016501109A1 (en) Novel anti-dpep3 antibodies and methods of use
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2017011344A (es) Anticuerpos diseñados de sitio específico y métodos de uso.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
EA201792312A1 (ru) Конструкции на основе калихеамицина и способы их применения
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.